Opening book details…
Can I read Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020 on EtoBox?
Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020 by David J. Newman is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.
What is Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020 about?
As of early November 2020, there are 10 approved antibody drug conjugates (ADCs) plus two others that are not usually listed. In addition, there are 70 ADCs at stages from phase I to phase III and 23 that are at the preclinical stage. The warheads of all of these drugs and drug candidates have their origins in natural product structures. The sources and modifications are discussed in general and then specifically commented on in each case with either the generic name if known and/or the ADC's ID names. Interestingly, almost all warheads listed are from microbial sources though initially a number were thought to have been from plants. The latest NCT numbers from Clintrials.gov of all phase I to phase III candidates are also given. Three unusual ADCs are also discussed, two of which (an antitumor agent and one directed against autoimmune diseases) are not usually listed as ADCs, with the third being an anti-infective.
Who reads Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020?
It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.
- Author
- David J. Newman
- Publisher
- American Chemical Society (ACS)
- Published
- 2021
- Language
- EN
- Field
- Biochemistry, Genetics and Molecular Biology (Life Sciences)